Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
90.42 CHF | +1.46% | +6.96% | +6.52% |
Apr. 24 | BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating | MT |
Apr. 24 | Novartis Says New Malaria Drug Formulation Safe and Effective for Babies | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.35% | 199B | |
+23.55% | 562B | |
-5.03% | 358B | |
+19.24% | 322B | |
+8.31% | 297B | |
+12.28% | 219B | |
-9.90% | 196B | |
-8.41% | 149B | |
-5.08% | 146B | |
+2.19% | 117B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis : Skin Disease Treatment Ligelizumab Gets US FDA's Breakthrough Therapy Designation